Loading…
Loading…
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) published in JAMA Dermatology. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected relapse earlier.MCC is a rare but aggressive ski.
California Public Employees Retirement System lessened its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 23.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,151 shares of the medical research company's stock after selling 52,312 shares during the
Fifth Third Bancorp boosted its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 3,373.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,253 shares of the medical research company's stock after purchasing an additional 10,929 shares during
Amova Asset Management Americas Inc. reduced its position in Natera, Inc. (NASDAQ: NTRA) by 10.1% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 423,424 shares of the medical research company's stock after selling 47,660 shares during the quarter.
Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biotech names on wildly different trajectories, the one semiconductor stock nobody can ignore, and an Argentine oil producer sitting on a shale reserve about to unlock its first export pipeline.
Allspring Global Investments Holdings LLC grew its holdings in Natera, Inc. (NASDAQ: NTRA) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 463,477 shares of the medical research company's stock after purchasing an additional 8,979 shares during the quarter.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:Kidney: 6 tests in year 1; 4 per year in years 2-3. “For-cause” coverage remai.
It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for NTRA and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.